Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin AB RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024
| ROM Etf | USD 72.05 1.97 2.66% |
About 62% of ProShares Ultra's investor base is looking to short. The current sentiment regarding investing in ProShares Ultra Technology etf implies that many traders are alarmed. ProShares Ultra's investing sentiment overview a quick insight into current market opportunities from investing in ProShares Ultra Technology. Many technical investors use ProShares Ultra Tech etf news signals to limit their universe of possible portfolio assets and to time the market correctly.
ProShares Ultra etf news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of ProShares daily returns and investor perception about the current price of ProShares Ultra Technology as well as its diversification or hedging effects on your existing portfolios.
ProShares |
SOUTH SAN FRANCISCO, Calif., December 09, 2024--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced a poster for preclinical data on CID-078, a first-in-class oral macrocycle cyclin AB RxL inhibitor, will be presented at the San Antonio Breast Cancer Symposium 2024. The event, which runs from December 10-13, brings together global leaders in breast cancer research and treatment.
Read at finance.yahoo.com
 |
ProShares Ultra Fundamental Analysis
We analyze ProShares Ultra's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProShares Ultra using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProShares Ultra based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Last Dividend Paid
Last Dividend Paid Comparative Analysis
ProShares Ultra is currently under evaluation in last dividend paid as compared to similar ETFs. Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
ProShares Ultra Tech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ProShares Ultra etf to make a market-neutral strategy. Peer analysis of ProShares Ultra could also be used in its relative valuation, which is a method of valuing ProShares Ultra by comparing valuation metrics with similar companies.
Peers
ProShares Ultra Related Equities
| UCC | ProShares Ultra | 0.34 | ||||
| UXI | ProShares Ultra | 0.59 | ||||
| RXL | ProShares Ultra | 0.99 | ||||
| UPW | ProShares Ultra | 1.71 | ||||
| USD | ProShares Ultra | 5.55 |
Check out ProShares Ultra Hype Analysis, ProShares Ultra Correlation and ProShares Ultra Performance. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
The market value of ProShares Ultra Tech is measured differently than its book value, which is the value of ProShares that is recorded on the company's balance sheet. Investors also form their own opinion of ProShares Ultra's value that differs from its market value or its book value, called intrinsic value, which is ProShares Ultra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProShares Ultra's market value can be influenced by many factors that don't directly affect ProShares Ultra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProShares Ultra's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProShares Ultra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProShares Ultra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.